<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>List of candidate vaccines currently under clinical trials</p>
 </caption>
 <alt-text id="alttext0070">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Platform</th>
    <th>Type of candidate vaccine</th>
    <th>Developer</th>
    <th>Coronavirus target</th>
    <th>The current stage of clinical evaluation/regulatory status Coronavirus candidate</th>
    <th>Same platform for non-coronavirus candidates</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Non-replicating viral vector</td>
    <td>ChAdOx1-S</td>
    <td>University of Oxford/AstraZeneca</td>
    <td>SARS-CoV-2</td>
    <td>Phase 3 ISRCTN89951424
     <break/>Phase2b/3
     <break/>2020-001228-32
     <break/>Phase 1/2 PACTR202006922165132
     <break/>2020-001072-15
    </td>
    <td>MERS, influenza, TB, Chikungunya, Zika, MenB, plague</td>
   </tr>
   <tr>
    <td>Non- Replicating Viral Vector</td>
    <td>Adenovirus Type 5 Vector</td>
    <td>CanSino Biological Inc./Beijing Institute of Biotechnology</td>
    <td>SARS-CoV-2</td>
    <td>Phase 2 ChiCTR2000031781
     <break/>Phase 1
     <break/>ChiCTR2000030906
    </td>
    <td>Ebola</td>
   </tr>
   <tr>
    <td>RNA</td>
    <td>LNP-
     <break/>encapsulated mRNA
    </td>
    <td>Moderna/NIAID</td>
    <td>SARS-CoV-2</td>
    <td>Phase 2 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04405076" id="intref0065" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04405076</ext-link>
     <break/>Phase 1 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04283461" id="intref0070" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04283461</ext-link>
    </td>
    <td>multiple candidates</td>
   </tr>
   <tr>
    <td>DNA</td>
    <td>DNA plasmid vaccine with electroporation</td>
    <td>Inovio Pharmaceuticals/International Vaccine Institute</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1/2 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04447781" id="intref0075" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04447781</ext-link>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336410" id="intref0080" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04336410</ext-link>
    </td>
    <td>multiple candidates</td>
   </tr>
   <tr>
    <td>Inactivated</td>
    <td>Inactivated</td>
    <td>Wuhan Institute of Biological
     <break/>Products/Sinopharm
    </td>
    <td>SARS-CoV-2</td>
    <td>Phase 1/2 ChiCTR2000031809</td>
    <td/>
   </tr>
   <tr>
    <td>Inactivated</td>
    <td>Inactivated</td>
    <td>Beijing Institute of Biological Products/Sinopharm</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1/2 ChiCTR2000032459</td>
    <td/>
   </tr>
   <tr>
    <td>Inactivated</td>
    <td>Inactivated + alum</td>
    <td>Sinovac</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1/2 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04383574" id="intref0090" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04383574</ext-link>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04352608" id="intref0095" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04352608</ext-link>
    </td>
    <td>SARS</td>
   </tr>
   <tr>
    <td>Protein Subunit</td>
    <td>Full-length recombinant SARS CoV-2
     <break/>glycoprotein nanoparticle vaccine adjuvanted with
     <break/>Matrix M
    </td>
    <td>Novavax</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1/2 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368988" id="intref0100" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04368988</ext-link>
    </td>
    <td>RSV; CCHF, HPV, VZV, EBOV</td>
   </tr>
   <tr>
    <td>RNA</td>
    <td>3 LNP-mRNAs</td>
    <td>BioNTech/Fosun Pharma/Pfizer</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1/2
     <break/>2020-001038-36
     <break/>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368728" id="intref0105" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04368728</ext-link>
    </td>
    <td/>
   </tr>
   <tr>
    <td>Inactivated</td>
    <td>Inactivated</td>
    <td>Institute of Medical Biology
     <break/>, Chinese Academy of Medical Sciences
    </td>
    <td>SARS-CoV-2</td>
    <td>Phase 1 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04412538" id="intref0110" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04412538</ext-link>
    </td>
    <td/>
   </tr>
   <tr>
    <td>DNA</td>
    <td>DNA Vaccine
     <break/>(GX-19)
    </td>
    <td>Genexine Consortium</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1
     <break/>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04445389" id="intref0115" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04445389</ext-link>
    </td>
    <td/>
   </tr>
   <tr>
    <td>Non- Replicating
     <break/>Viral Vector
    </td>
    <td>Adeno-based</td>
    <td>Gamaleya Research Institute</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04436471" id="intref0120" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04436471</ext-link>
     <break/>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04437875" id="intref0125" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04437875</ext-link>
    </td>
    <td/>
   </tr>
   <tr>
    <td>Protein Subunit</td>
    <td>Native like Trimeric subunit Spike Protein vaccine</td>
    <td>Clover Biopharmaceuticals Inc./GSK/Dynavax</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04405908" id="intref0130" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04405908</ext-link>
    </td>
    <td>HIV, REV Influenza</td>
   </tr>
   <tr>
    <td>Protein Subunit</td>
    <td>Adjuvanted recombinant protein (RBD-Dimer)</td>
    <td>Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of
     <break/>Sciences
    </td>
    <td>SARS-CoV-2</td>
    <td>Phase 1 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04445194" id="intref0135" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04445194</ext-link>
    </td>
    <td>MERS</td>
   </tr>
   <tr>
    <td>Protein Subunit</td>
    <td>Recombinant spike protein with Advax™
     <break/>Adjuvant
    </td>
    <td>Vaxine Pty Ltd/Medytox</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04453852" id="intref0140" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04453852</ext-link>
    </td>
    <td/>
   </tr>
   <tr>
    <td>RNA</td>
    <td>LNP-nCoVsaRNA</td>
    <td>Imperial College London</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1
     <break/>ISRCTN17072692
    </td>
    <td>EBOV; LASV, MARV,
     <break/>Inf (H7N9), RABV
    </td>
   </tr>
   <tr>
    <td>RNA</td>
    <td>mRNA</td>
    <td>Curevac</td>
    <td>SARS-CoV-2</td>
    <td>Phase 1 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04449276" id="intref0145" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04449276</ext-link>
    </td>
    <td>RABV, LASV, YFV; MERS, InfA, ZIKV,
     <break/>DENV, NIPV
    </td>
   </tr>
   <tr>
    <td>RNA</td>
    <td>mRNA</td>
    <td>People's Liberation Army (PLA) Academy of Military
     <break/>Sciences/Walva × Biotech.
    </td>
    <td>SARS-CoV-2</td>
    <td>Phase 1 ChiCTR2000034112</td>
    <td/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Abbreviations: CCHF, Crimean–Congo haemorrhagic fever virus; DENV, dengue virus; EBOV, Ebola virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; Inf (H7N9), influenza virus H7N9; LASV, Lassa mammarenavirus; MARV, Marburg virus; MenB, meningitis B; MERS, Middle East respiratory syndrome; NIPV, Nipah virus; RABV, rabies virus; REV, reticuloendothelial virus; RSV, respiratory syncytial virus; SARS, severe acute respiratory syndrome; TB, tuberculosis; VZV, varicella zoster virus.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
